EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.
